Saint Luke's Cancer Institute - Nampa — Nampa, Idaho

Saint Luke's Cancer Institute - Nampa is a clinical research site located in Nampa, Idaho, United States 83687.

Crixeo Clinical Trials Trust Score: 35/100 (FAILING). This profile has not yet been claimed by the site owner.

Saint Luke's Cancer Institute - Nampa has participated in 238 clinical trials with 190 currently active.

Therapeutic areas: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma.

Sponsors: National Cancer Institute (NCI), Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Nampa

Browse all research sites in Idaho · View every site in Nampa

Sponsor Feasibility Report

Trust Score: 35/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Saint Luke's Cancer Institute - Nampa?

Saint Luke's Cancer Institute - Nampa has a Crixeo Trust Score of 35/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Saint Luke's Cancer Institute - Nampa conducted?

Saint Luke's Cancer Institute - Nampa has 238 clinical trials on record, with 190 currently active. Their work covers Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma.

Is Saint Luke's Cancer Institute - Nampa accredited by Crixeo Clinical Trials?

Saint Luke's Cancer Institute - Nampa has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Saint Luke's Cancer Institute - Nampa?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.